## Amendments to the Claims:

Claim 1. (Currently amended): A purified polypeptide, consisting essentially of comprising anamino acid sequence selected from the group consisting of: a) sequence SEQ ID No. 2; b) sequence SEQ ID No. 4; c) sequence SEQ ID No. 6; d) sequence SEQ ID No. 8; e) sequence SEQ ID No. 10; f) sequence SEQ-ID No. 13; g) sequence SEQ ID No. 15; h) sequence SEQ ID No. 17; and i) sequence SEQ-ID No. 19. Claim 2. (Cancelled) Claim 3. (Currently amended): A purified polypeptide according to Claim 1 comprising an-amino acid sequence selected from the group consisting of SEQ ID No. 2 from residue 110 to residue 310, SEQ ID No. 6 from residue 110 to residue 310, and SEQ-ID No. 8 from residue 60 to residue 260. Claim 4. (Previously amended): A polypeptide according to Claim 1, which is produced from an alternative splicing of messenger RNA of a gene coding for said polypeptide. Claim 5. (Previously amended): A polypeptide according to Claim 1 that is a recombinant polypeptide produced in the form of a fusion protein. Claims 6-39 (cancelled)

Claim 40. (new): A composition comprising SEQ ID NO:6 and a pharmaceutically acceptable vehicle.